

UPDATE ON PRESBYACUSIS

James Keir DOHNS MRCS

Specialist Registrar in

Otorhinolaryngology

North Cheshire Hospitals NHS Trust

UK

Email: jameskeir@hotmail.com

Introduction

Presbycusis or age-related hearing loss (ARHL) is the 'the natural failure of hearing with advancing years, caused by degenerative changes in the internal ear'.¹ It is a common condition, increasingly prevalent with age and with the rate of decline accelerating with advancing age.^{2, 3} In 1999, the World Health Organization estimated that 580 million people over the age of 60 suffered from hearing loss worldwide. By 2020, it is anticipated that this number will have increased by 75% resulting in over one billion people of 60 years or older being affected.⁴

The condition is characterised by bilateral, symmetrical changes leading from an initial high to low frequency sensorineural hearing loss (SNHL). Zwaardemaker, who originally described the condition, noted this when producing a series of notes in octaves via Galton's whistles for children and the elderly. It was noted that the highest octaves could not be heard by the elderly and it was concluded that high frequency hearing loss occurred in this group.⁵

The complexity of the underlying processes involved in presbycusis are now being realised and it is noted that the progression and age-related onset of this condition are very variable, suggesting a multifactorial aetiology. Both extrinsic factors, such as noise exposure and intrinsic factors, such as systemic conditions and genetics are thought to play a part in the resulting SNHL.

Pathophysiology

Ageing results in histological, electrophysiological and molecular changes in the cochlea. Histological studies have repeatedly found degenerative changes in the stria vascularis, spiral ganglion cells, inner hair cells, and outer hair cells that are associated with the severity of hearing loss.⁶

Schunknecht⁷ subdivided these changes into sensory ARHL (high frequency loss; loss of sensory cells), stria or metabolic (flat descending threshold pattern; atrophy of stria vascularis), neural ARHL (loss of word discrimination; loss of cochlear neurons) and cochlear conductive or mechanical ARHL (unknown pathology). However, many patients show a mixture of these pathologies.⁸

Aetiology

Extrinsic factors thought to contribute to ARHL include noise exposure, ototoxic medication, chemical exposure and medical conditions.

Four studies have investigated the progression of ARHL in isolated communities with relatively low levels of noise exposure.⁹⁻¹² These cross sectional studies of the Mabaan tribe of Sudan,⁹ an isolated hill dwelling tribe in India,¹⁰ Orkney Islanders¹¹ and Kalahari Bushmen¹² found better preservation of hearing into old age. Furthermore, animal studies have demonstrated that noise exposure earlier in life leads to an increased vulnerability to ARHL,¹³ with specific genes conferring increased susceptibility to this within species.¹⁴

Ototoxic medication such as aminoglycosides and platinum based chemotherapy agents may accelerate presbycusis in older subjects. This may be related to increased use of these medications in this group and elevated drug levels in blood due to altered renal and hepatic function.⁸ Industrial chemicals are also known to cause a higher prevalence of high frequency hearing loss, including toluene, trichloroethylene, styrene and xylene.^{15, 16}

Several medical conditions, including diabetes and cardiovascular disease have been shown to have an association with ARHL. Diabetic patients are known to have a higher incidence of SNHL.¹⁷ Early onset high frequency SNHL compared to age matched controls¹⁸ and DNA mitochondrial mutations leading to both late onset diabetes and SNHL have been described.^{19, 20} Female patients with cardiovascular disease have been shown to be at increased risk for developing ARHL, with the gender difference thought to



Presbycusis

Photo: AuDNet, Inc

be related to hormonal differences.²¹ Animal studies²² have supported these findings with the proposed underlying mechanism related to cochlea hypoxia.²³

Intrinsic factors, in the form of genetic factors have been the subject of much recent research interest. Using inbred mice, Erway²⁴ et al were able to demonstrate recessive alleles at three loci which contributed to the development of ARHL. Age-related hearing loss 1 (*Ahl1*) gene was subsequently mapped to chromosome 10 and was found to overlap with the modifier of the deaf waddler locus (*mdfw*) region in 10 strains of inbred mice including C57BL/6J, 129P1/ReJ, BALB/cByJ, A/J, BUB/BnJ, C57BR/cdJ, DBA/2J, NOD/LtJ, SKH2/J and STOCK760. The gene was demonstrated to elevate hearing thresholds in middle-aged and old mice at high frequencies.²⁵⁻²⁷ Mice that were then genetically engineered to be identical to the C57BL/6J strain in all but *Ahl1* were found to be protected against early onset hearing loss. However, older mice still developed hearing loss. It is, therefore, proposed that more than one loci contributes to the hearing loss changes in these mice.⁸ Noben-Trauth et al²⁸ were able to demonstrate that this gene may be allelic to Cadherin 23 and, thus, the latter may be an important gene in ARHL, as well as congenital hearing loss. Subsequent studies identified *Ahl2* and *Ahl3* on chromosome 5 and 17, respectively, in certain sub-species of mice.²⁹⁻³¹

Prevention and Treatment

Prevention of presbycusis should address predisposing factors and would include:

- Education to raise awareness of the consequences of noise exposure
- Legislation to restrict noise exposure
- Combining ototoxic medications with protective agents, such as antioxidants and free radical scavengers in high risk groups
- Legislation to protect 'at risk' workers exposed to hazardous industrial chemicals
- Optimisation of the care of those with diabetes and cardiovascular disease.

At present the mainstay of treatment remains provision of hearing aids with amplification of sounds. However, problems remain with poor speech recognition and with differentiation of sound in noisy environments.

Promising future interventions include gene therapy and stem cell implantation and there have been promising results in animal models. In gene therapy, the introduction of *Math1*, a gene responsible for the development of hair cells in the cochlea, has been demonstrated to lead to the re-growth of hair cells which resulted in improvement in thresholds.³² Stem cells implanted in the inner ear have been demonstrated to survive, migrate, differentiate and extend nerve projections in the auditory system of adult mammals.³³

Conclusion

ARHL is an increasingly prevalent condition which results in a deterioration in quality of life, communication problems and, subsequently, affects socio-economic status. It is caused by degenerative changes in the cochlea, as a result of multifactorial extrinsic and intrinsic contributions. Further investigation into the genetic factors in humans is important - and exciting areas for future interventions include gene and stem cell therapy.

References

1. Butterworths Medical Dictionary. Critchley M. 2nd Ed., Butterworth and Co., London (1990).
2. Hearing in Adults. Davis A. Whurr Publishers, London (1995).
3. Longitudinal study of hearing. Davis AC, Ostri B, Parving A. *Acta Otolaryngol Suppl.* 1991; **476**: 12–22.
4. World Health Organization (accessed at <http://www.who.int/en/>).
5. Der Verlust au hohen Tönen mit zunehmendem Alter. Ein neues Gesetz. Zwarardemaker H. *Arch Ohr Nas und Kehlkopfheilkunde.* 1874; **32**: 53–56.
6. Presbycusis: A Human Temporal Bone Study of Individuals with Downward Sloping Audiometric Patterns of Hearing Loss and Review of the Literature. Nelson E G, Hinojosa R. *Laryngoscope.* 2006; **116**(9); Supplement Part 3: 1–12.
7. Cochlear pathology in presbycusis. Schuknecht HF, Gacek MR. *Ann Otol Rhinol Laryngol.* 1993; **102**: 1–16.
8. The complexity of age related hearing impairment: contributing environmental and genetic factors. Van Eyken E, Van Camp G, Van Laer L. *Audiol Neurotol.* 2007; **12**(6): 345–358.
9. Presbycusis study of a relatively noise free population in the Sudan. Rosen S, Bergman M, Plester D, El-Mofty A, Satti MH. *Ann Otol Rhinol Laryngol.* 1962; **71**: 727–743.
10. Hearing of Todas of South India. Kapur YP, Patt AJ. *Arch Otolaryngol Head Neck Surg.* 1967; **85**: 400–406.
11. Hearing thresholds in an island population in North Scotland. Kell RL, Pearson JCC, Taylor W. *Int Audiol.* 1970; **9**: 334–339.
12. The acuity of hearing in the Kalahari Bushmen. A pilot survey. Jarvis JF, Van Heerden HG. *J Laryngol Otol.* 1967; **81**: 63–68.
13. Acceleration of age-related hearing loss by early noise exposure: evidence of a misspent youth. Kujawa SG, Liberman MC. *J Neurosci.* 2006; **26**: 2115–2123.
14. Vulnerability to noise-induced hearing loss in 'middle-aged' and young adult mice: a dose response approach in CBA, C57BL, and BALB inbred strains. Ohlemiller KK, Wright JS, Heidbreder AF. *Hear Res.* 2000; **149**: 239–247.
15. Effect of industrial solvents on hearing. Johnson AC, Nylen PR. *Occup Med.* 1995; **10**: 623–640.
16. Audiometric findings in workers exposed to low levels of styrene and noise. Morata TC, Johnson AC, Nylen P, et al. *J Occup Environ Med.* 2002; **44**: 806–814.
17. The effect of diabetes on sensorineural hearing loss. Kakarlapudi V, Sawyer R, Staeker H. *Otol Neurotol.* 2003; **24**: 382–386.
18. A 5-year prospective study of diabetes and hearing loss in a veteran population. Vaughan N, James K, McDermott D, et al. *Otol Neurotol.* 2006; **27**: 37–43.
19. The diabetes-associated 3243 mutation in the mitochondrial tRNA(Leu(UUR)) gene causes severe mitochondrial dysfunction without a strong decrease in protein synthesis rate. Janssen GM, Maassen JA, van Den Ouweland JM. *J Biol Chem.* 1999; **274**: 29744–29748.
20. Hearing threshold in patients with diabetes mellitus. Kurien M, Thomas K, Bhanu TS. *J Laryngol.* 1989; **103**: 164–168.
21. The association between cardiovascular disease and cochlear function in older adults. Torre P 3rd, Cruickshanks KJ, Klein BE, et al. *J Speech Lang Hear Res.* 2005; **48**: 473–481.
22. Age-dependent modifications of expression level of VEGF and its receptors in the inner ear. Picciotti P, Torsello A, Wolf FI, et al. *Exp Gerontol.* 2004; **39**: 1253–1258.
23. Correlation of cochlear blood supply with mitochondrial DNA common deletion in presbycusis. Dai P, Yang W, Jiang S, Gu R, Yuan H, Han D, Guo W, Cao J. *Acta Otolaryngol.* 2004; **124**: 130–136.
24. Genetics of age-related hearing loss in mice. 1. Inbred and F1 hybrid strains. Erway LC, Willott JF, Archer JR, et al. *Hear Res.* 1993; **65**: 125–132.
25. A major gene affecting age-related hearing loss in C57BL/6J mice. Johnson KR, Erway LC, Cook SA, et al. *Hear Res.* 1997; **114**: 83–92.
26. A major gene affecting age-related hearing loss is common to at least ten inbred strains of mice. Johnson KR, Zheng QY, Erway LC. *Genomics.* 2000; **70**: 171–180.
27. Hearing loss associated with the modifier of deaf waddler (mdfw) locus corresponds with age-related hearing loss in 12 inbred strains of mice. Zheng QY, Johnson KR. *Hear Res.* 2001; **154**: 45–53.

28. Association of cadherin 23 with polygenic inheritance and genetic modification of sensorineural hearing loss. Noben-Trauth K, Zheng QY, Johnson KR. *Nat Genet.* 2003; **35**: 21–23.
29. Ahl2, a second locus affecting age-related hearing loss in mice. Johnson KR, Zheng QY. *Genomics.* 2002; **80**: 461–464.
30. Ahl3, a third locus on mouse chromosome 17 affecting age-related hearing loss. Nemoto M, Morita Y, Mishima Y, et al. *Biochem Biophys Res Commun.* 2004; **324**: 1283–1288.
31. Fine mapping of Ahl3 affecting both age-related and noise-induced hearing loss. Morita Y, Hirokawa S, Kikkawa Y, et al. *Biochem Biophys Res Commun.* 2007; **355**: 117–121.
32. Auditory hair cell replacement and hearing improvement by Atoh1 gene therapy in deaf mammals. Izumikawa M, Minoda R, Kawamoto K, et al. *Nat Med.* 2005; **11**: 271–276.
33. Cell replacement therapy in the inner ear. Hu Z, Ulfendahl M. *Stem Cells Dev.* 2006; **15**: 449–459. □

Book Review

TINNITUS: SOURCE READINGS (1841-1980)

Robert T Sataloff, Dimiter I Dentshev, Mary J Hawshaw (Eds.)

San Diego, Plural 2007
ISBN: 9781597561167

Plural Publishing Inc.
5521 Ruffin Road
San Diego
CA 92123
USA

Email:
information@pluralpublishing.com

This book is a compendium of historical but current literature on the subject of **tinnitus**, pre-dating the 20th century. The authors blamed the sluggish knowledge in the management of tinnitus on deficient research interests. In contrast, they presented the rich clinical acumen of the 19th century practitioners and showed very little improvement to what is already known on the subject. In providing a summary of historical but interesting and inspiring literature, the authors hope to stimulate more research which would lead to improvements in the current management of tinnitus.

The book chapters are of unequal length but the layout is easy to follow. Chapter 1, which is the 'Overview of Tinnitus', provided a very good introductory background on the aetiology and management of this condition. The second chapter, on the 'Receptors in the Auditory Pathway', is a summary of the basic science of neurotransmission and an essential component in its understanding and future research needs. Chapters 3 to 7 outline the 140 years historical review of the case reports which dominated the

publications in the 19th century. The first case report was from the *Lancet*, in 1841, and the last one, in 1897, was published in *Laryngoscope*. Extensive publications on the management of tinnitus dominated the early and mid 20th century database and ranged from the anticoagulant treatment of sudden deafness (*J Laryngol.* 1964; **78**: 583–586) to a subject which 'everybody talks about it but nobody does anything about it' (*Eye, Ear, Nose Throat Monthly.* 1965; **44**: 311).

I would have loved to see a list of the Source Articles discussed in this book

for ease of reference. Notwithstanding, this is a welcome addition to the subject of tinnitus, which has more or less remained elusive to practitioners in this field for more than a century.

Bolajoko O Olusanya
College of Medicine
University of Lagos
Surulere
Nigeria

E-mail: boolusanya@aol.com □

